The Challenge
Complex Safety Profile in a Crowded Therapeutic Space
The client was preparing a BLA submission for a first-in-class PD-1/LAG-3 bispecific antibody for second-line NSCLC. While the pivotal Phase 3 trial (N=1,247) demonstrated statistically significant improvement in overall survival versus standard-of-care pembrolizumab, the novel mechanism introduced a safety profile with unique characteristics that required careful characterization.
The specific challenges facing the regulatory team were multifaceted:
- Novel immune-related adverse events: The bispecific mechanism targeting both PD-1 and LAG-3 produced a distinct pattern of immune-related adverse events (irAEs) not seen with monospecific anti-PD-1 agents, including a higher incidence of Grade 2-3 hepatitis (8.3% vs. 3.1%) and a novel pattern of autoimmune thyroiditis
- Regulatory scrutiny: FDA reviewers had flagged the hepatotoxicity signal during a pre-BLA meeting and requested a comprehensive benefit-risk assessment demonstrating that the survival benefit justified the incremental safety risk
- Competitive context: With multiple PD-(L)1 agents already approved for second-line NSCLC, the benefit-risk assessment needed to clearly demonstrate added clinical value to support both regulatory approval and subsequent market access
- Data volume: The integrated safety database included 3,842 patients across the development program (Phase 1-3), plus post-marketing safety data from the first-line indication approved 8 months earlier. The team needed to synthesize data from 14 clinical studies, 2 ongoing registries, and published literature on the therapeutic class
- Timeline pressure: The BLA submission date was fixed, with only 16 weeks remaining. The benefit-risk assessment was on the critical path, and the manual process was estimated at 30+ weeks
The Solution
ArcaScience Platform Deployment
ArcaScience deployed its full platform suite—Data Intelligence, Decision Intelligence, and Automated Outputs—to create a comprehensive, quantitative benefit-risk assessment that met regulatory expectations while fitting within the compressed timeline.
Implementation Process
Results
preparation time
(vs. 30-week manual estimate)
benefit-risk balance
Quantitative Outcomes
| Metric | Manual Estimate | ArcaScience Actual |
|---|---|---|
| Time to complete BRA | 30 weeks | 12 weeks |
| FTE effort | 12 FTEs | 5 FTEs |
| Data sources integrated | 3-4 (manually) | 14 studies + 2 registries + literature |
| Sensitivity scenarios | 10-15 (manual) | 50,000 (Monte Carlo) |
| New safety signals identified | 0 (known signals only) | 3 (including 1 requiring label language) |
| Cost of BRA preparation | $1.8M estimated | $720K actual |
Regulatory Outcome
The BLA was accepted for filing without a Refuse to File letter. During the review cycle, the FDA issued 14 information requests; notably, none were related to the benefit-risk assessment—a significant achievement given the pre-BLA feedback on hepatotoxicity concerns. The advisory committee voted 11-2 in favor of approval, with multiple committee members commenting favorably on the transparency and rigor of the benefit-risk analysis.
The product received FDA approval with standard prescribing information that included the hepatotoxicity risk in Warnings and Precautions rather than as a Boxed Warning—an outcome the team attributed in part to the quantitative demonstration that the overall benefit-risk profile remained favorable even under the most conservative risk assumptions.
Unexpected Value
The AI-powered safety signal analysis identified a previously unrecognized pattern of late-onset (>12 months) autoimmune thyroiditis that occurred at a rate of 4.7% in the treatment arm. Because this signal was identified during BLA preparation rather than post-marketing, the company was able to proactively include monitoring recommendations in the prescribing information and risk management plan. This proactive approach was noted favorably by both FDA reviewers and the advisory committee, and prevented what would likely have been a post-marketing safety signal requiring a label supplement.
Key Takeaways
- Quantitative BRA can be achieved on regulatory timelines when supported by AI-driven data integration and analysis. The 60% time reduction was achieved without sacrificing analytical rigor.
- AI-powered signal detection adds value beyond efficiency. The identification of three new safety signals, including one that influenced labeling decisions, demonstrates that AI analysis can uncover clinically meaningful findings that manual review might miss.
- Regulatory agencies respond positively to structured quantitative approaches. The absence of benefit-risk-related information requests and the advisory committee's favorable comments validate the investment in rigorous methodology.
- Proactive risk characterization benefits all stakeholders. By identifying and addressing the thyroiditis signal before approval, the company protected patients, demonstrated good pharmacovigilance practice, and avoided post-marketing regulatory actions.
- The cost savings are substantial and real. The $1.08M savings on a single BRA preparation represents a strong ROI, and the platform continues to provide value through living benefit-risk updates for the product's post-marketing lifecycle.
Ready to Transform Your Benefit-Risk Strategy?
Learn how ArcaScience can support your next regulatory submission with AI-driven benefit-risk analysis.